CRP and pachyonychia congenita: Lastly, we report solely perioperative outcomes but lack the oncologic and survival data, e.g., PSA response, progression-free and overall survival, necessary to sufficiently scrutinize the role of MP or SP CRP for patients with metastatic castrate sensitive PC.